MicroRNAs as Key Regulators and Potential Biomarkers in Vitiligo Pathogenesis

IF 2.2 4区医学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Gene Medicine Pub Date : 2026-01-08 DOI:10.1002/jgm.70083

Ahmed S. Doghish, Nehal I. Rizk, Osama A. Mohammed, Mohamed Hemdan, Khaled M. Alam-Eldein, Mohamed Salah Basiouny, Khaled Abuelhaded, Hend H. Mohamed, Abanoub A. S. Shaker, Moaz M. Elshafey, Alaa Adel Abo Ella, Reda M. Mansour

引用次数: 0

Abstract

Vitiligo involves melanocyte loss, potentially due to oxidative stress, immune dysfunction, and genetics. This article examines microRNAs (miRNAs), noncoding RNAs crucial for gene expression regulation, as they act as molecular switches that can activate or deactivate genes upon translation. It identifies modified miRNA levels in the skin, blood, immune cells, and exosomes of vitiligo patients. These miRNAs are essential for melanocyte viability and for modulating oxidative stress and immunological responses. Specific miRNAs may function as diagnostic or prognostic biomarkers. The review offers an in-depth comprehension of the crucial functions of miRNAs in development.

Abstract Image

查看原文本刊更多论文

MicroRNAs作为白癜风发病机制的关键调控因子和潜在生物标志物

白癜风涉及黑素细胞的损失，可能是由于氧化应激、免疫功能障碍和遗传。本文研究了microRNAs (miRNAs)，一种对基因表达调控至关重要的非编码rna，因为它们作为分子开关，可以在翻译时激活或灭活基因。它鉴定了白癜风患者皮肤、血液、免疫细胞和外泌体中修饰的miRNA水平。这些mirna对黑素细胞的活力和调节氧化应激和免疫反应至关重要。特异的mirna可作为诊断或预后的生物标志物。这篇综述提供了对mirna在发育中的关键功能的深入理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gene Medicine 医学-生物工程与应用微生物

CiteScore

6.40

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The aims and scope of The Journal of Gene Medicine include cutting-edge science of gene transfer and its applications in gene and cell therapy, genome editing with precision nucleases, epigenetic modifications of host genome by small molecules, siRNA, microRNA and other noncoding RNAs as therapeutic gene-modulating agents or targets, biomarkers for precision medicine, and gene-based prognostic/diagnostic studies. Key areas of interest are the design of novel synthetic and viral vectors, novel therapeutic nucleic acids such as mRNA, modified microRNAs and siRNAs, antagomirs, aptamers, antisense and exon-skipping agents, refined genome editing tools using nucleic acid /protein combinations, physically or biologically targeted delivery and gene modulation, ex vivo or in vivo pharmacological studies including animal models, and human clinical trials. Papers presenting research into the mechanisms underlying transfer and action of gene medicines, the application of the new technologies for stem cell modification or nucleic acid based vaccines, the identification of new genetic or epigenetic variations as biomarkers to direct precision medicine, and the preclinical/clinical development of gene/expression signatures indicative of diagnosis or predictive of prognosis are also encouraged.